cjc-1295 ipamorelin safety side effects 2026 profile CJC-1295 Review: Mechanism, Uses, Safety & FDA Status CJC-1295 / Ipamorelin Peptide Therapy:

Whether exogenous ipamorelin enhances or disrupts natural sleep-related GH pulsatility depends on timing, dose, and individual factors that have not been systematically studied

Published data describe: Sustained IGF-1 elevation at 5-8 days post-injection Greater water retention and hand-tingling reports than non-DAC in community sources Trial data on serious adverse events: none reported at studied doses Ipamorelin The Raun and Ankersen papers (PMID 9849822

Brain Behav Immun 79:7590

Filetti, C

Daylight savings time is already accounted for by a shift in the UTC offset, so no additional work is required to account for this during data analysis